PURASORB PLD 9655 is a medical-device-grade poly(L-lactide-co-D,L-lactide) with an L-lactide:D-lactide molar ratio of 96:4 and an inherent viscosity midpoint of 0.55 dL/g measured in chloroform at 25 °C, 0.1 g/dL. Differential scanning calorimetry at 10 °C/min shows a glass transition of 57–61 °C and a broad melting endotherm between 145 °C and 165 °C; the D-lactide co-units break stereoregularity and depress the melting point relative to high-optical-purity PLLA, which is the core mechanism used downstream in melt spinning, injection molding, and solvent processing. Because the resin is supplied for medical-device fabrication, all downstream operations require polymer moisture below 100 ppm and residual lactide monomer values confirmed against the lot certificate. At ambient relative humidity above 60 %, open-pellet residence time should not exceed 20 min unless the hopper is purged with dried air.

Melt-spun absorbable monofilament suture filaments manufactured from PLD 9655 require a desiccant-bed drying step that brings hopper-air dew point to −40 °C or lower for 4–6 h at 60–70 °C, reducing polymer moisture to below 100 ppm. On a single-screw extruder with a 24:1 L/D barrier screw, barrel temperatures set at 175–185 °C in the feed zone, 190–200 °C in compression, 200–210 °C in metering, and 205–215 °C at the die head hold melt temperature near 210 °C without exceeding the copolymer’s upper thermal ceiling; barrel residence time is kept below 6 min because hydrolytic chain scission lowers inherent viscosity and produces melt-pressure fluctuation. A metering gear pump with less than 0.2 % discharge variation feeds a spinneret pack with sintered-metal filtration of 15–25 µm. Quench-bath temperature of 25–35 °C and a two-stage hot-draw sequence at draw ratios of 1.05:1 followed by 3.5:1–4.5:1 at 70–85 °C orient the monofilament; annealing under tension at 90–100 °C for 6–8 h reduces free shrinkage to below 1 %. For melt lubrication, 0.02–0.06 wt% calcium stearate is added; above 0.10 wt% die-lip plate-out and reduced knot-pull force appear in production trials. Compliance for absorbable sutures is anchored to ISO 10993-1:2018 for biological evaluation planning, ISO 10993-5:2009 and ISO 10993-10:2010 for local tissue response, ISO 13781:2017 for in vitro degradation of lactide copolymers, and USP <861> for suture diameter and knot-pull tensile strength; ASTM F1635-16 applies to hydrolysis of fabricated suture forms. Terminal product types include monofilament sutures in USP 5/0–2, pre-oriented barbed suture cores after cutting, and braided suture components following further yarn texturing.

Why Does Injection Molding of 96:4 L/D-Lactide Copolymer Require Screw Recovery Times Below 8 Seconds?

Injection molding of PLD 9655 into load-bearing absorbable fixation devices is limited by the copolymer’s narrow melt-temperature window and shear-heating behavior. Production-scale electric injection molding machines with 40–80 t clamp force and 20–25 mm diameter screws run at 80–120 rpm; screw recovery times above 8 s at backpressure above 10 bar expose the material to progressive autocatalytic hydrolysis. Barrel setpoints of 170 °C at the feed throat, 180–190 °C in the compression zone, 190–195 °C in the metering zone, and 195 °C at the nozzle keep melt temperature below 210 °C; mold temperature is held at 25–40 °C to allow skin crystallization without embrittlement. For osteoconductive grades, β-tricalcium phosphate is compounded into PLD 9655 at 10–30 wt% via a 25:1 L/D co-rotating twin-screw extruder with side-feeding at the L/D 15 port; two kneading blocks at 90° offset disperse the ceramic phase before pelletization. Published data for polylactide-β-TCP composites indicate that tensile strength retention after 26 weeks in phosphate-buffered saline at 37 °C remains above 50 % at 10–15 wt% loading but falls below 30 % above 20 wt% because particle agglomeration creates crack-initiation sites, as evaluated under ISO 13781:2017 immersion conditions. In actual molding runs, gate blush and brown specks appear when melt temperature exceeds 210 °C, indicating hydrolytic degradation by-products. Annex A of ISO 15814:1999 provides in vitro degradation comparisons for polylactide copolymers; ASTM F2502-17 covers absorbable plates and screws; ISO 10993-1:2018 and ISO 13781:2017 complete the qualification matrix. Pre-drying to below 100 ppm moisture is mandatory, and amine-based melt additives are excluded because they accelerate lactide copolymer chain scission. Terminal product types include interference screws, suture anchors, meniscal fixation darts, and craniofacial fixation plates.

In solvent extraction/evaporation manufacture of injectable depot microspheres, PLD 9655 is dissolved in dichloromethane at 10–20 wt% polymer, and the active pharmaceutical ingredient is either co-dissolved or dispersed at polymer-to-drug mass ratios between 5:1 and 20:1, depending on drug solubility and the desired lag phase before release. The oil phase is emulsified into a continuous aqueous phase of 0.5–2.0 wt% polyvinyl alcohol under high-shear dispersion; the resulting emulsion is transferred to an extraction vessel maintained at pH 7.2–7.4, where dichloromethane diffuses into the aqueous phase and PLD 9655 precipitates into microspheres with particle diameters from 10 µm to 75 µm. Solvent removal continues under reduced pressure at 15–20 °C for 4–6 h, followed by washing and lyophilization at −40 °C shelf temperature. The 96:4 L:D-lactide sequence controls release because D-lactide defects suppress spherulitic crystallization and slow the hydration front relative to high-glycolide PLGA, shifting diffusion lag phase from hours to days in pH 7.4 media as observed in USP apparatus 2 release testing at 37 °C; formulations above 20 wt% polymer in the oil phase increase encapsulation efficiency but create irregular multi-chamber particles visible in scanning electron microscopy lot rejects. Standards include USP <788> for particulate matter, USP <790> for injectable visible particulates, ISO 10993-1:2018, and ISO 13781:2017 for degradation-product monitoring. Published data for PLD 9655 with small-molecule drugs at the 5:1 ratio is limited; process capability must be established with batch-scale validation rather than extrapolated from PLGA systems. Terminal product types include peptide-loaded depots, intra-articular corticosteroid microspheres, and extended-release antipsychotic suspensions.

Electrospun Dural Patches and the 15 kV Solvent Evaporation Threshold

PLD 9655 can be electrospun from chloroform/dimethylformamide 80:20 v/v at polymer concentrations of 6–10 wt%, producing fiber diameters from 0.5 µm to 3.5 µm. The applied voltage is set to 12–18 kV with a spinneret-to-collector distance of 15 cm and a solution feed rate of 0.8–1.2 mL/h through an 18G blunt needle. Below 12 kV, low charge density causes periodic bead defects; above 18 kV, jet whipping broadens diameter polydispersity above 0.45 as measured from image analysis of 500 fibers per lot. For dural and vascular scaffolds, a rotating mandrel at 250–500 m/min surface speed orients fibers circumferentially and creates an anisotropic modulus ratio of 1.5:1–2.0:1. Vacuum drying at 40 °C for 24 h is required because residual DMF above 0.1 wt% produced positive cytotoxicity in ISO 10993-5:2009 production-lot validation. Porogen addition of 10–20 wt% sodium chloride sieved to 50–100 µm and leached in sterile water at 37 °C for 48 h creates interconnected pores while maintaining fiber architecture. The chlorinated solvent stream requires explosion-proof exhaust and batch solvent accounting under volatile-organic-compound permits. Standards include ASTM F2150-19 for scaffold mechanical and structural characterization, ISO 10993-1:2018, and ISO 13781:2017 for in vitro degradation. Terminal products include dural substitutes, vascular graft scaffolds, and anisotropic tendon-repair membranes.

Solvent-cast resorbable barrier membranes are produced from PLD 9655 at 8–12 wt% in chloroform, with polyethylene glycol 5–10 wt% as a water-soluble porogen to create interconnecting channels. Casting on siliconized glass at a doctor-blade wet film thickness of 60–80 µm, followed by controlled evaporation at ambient pressure for 12–16 h, produces dry membranes of 200–500 µm depending on casting gap and polymer concentration. Residual chloroform in the finished device is controlled to a maximum of 60 ppm; above this limit, direct-contact ISO 10993-5:2009 assays produced borderline cytotoxicity in membrane prototypes during qualification. Cut and sealed into preformed dental configurations, these membranes function as barriers in guided bone regeneration. Compliance relies on ISO 10993-1:2018, ISO 10993-6:2016 for local effects after implantation, ASTM F1635-16 for hydrolysis of fabricated forms, plus risk-management annexes under ISO 10993-1:2018. Terminal products include preformed dental barrier membranes, sinus floor elevation barriers, and periodontal defect membranes.

When Extrusion-Grade PLD 9655 Replaces Pellet Feedstock in Patient-Specific Fused Filament Fabrication

For patient-specific craniomaxillofacial scaffolds, PLD 9655 is compounded with 5–10 wt% hydroxyapatite or 10 wt% β-tricalcium phosphate to reduce melt sag, then extruded into 1.75 mm filament on a medical-grade single-screw extruder at 180–195 °C, with filament diameter tolerance of ±0.05 mm. During fused filament fabrication, a nozzle temperature of 190–210 °C and bed temperature of 25–35 °C produce layer adhesion within 0.15 mm layers. Nozzle temperatures below 180 °C cause under-extrusion and brittle interlayer fusion; above 215 °C, hydrolysis-induced bubble formation creates surface pitting and reduces flexural strength. Raster angle controls anisotropy: 0° rasters provide maximum tensile strength along the load path, while 45°/135° alternating rasters reduce brittle crack propagation but lower tensile strength by approximately 20–30 % in monotonic tensile testing per ASTM D638-14. Printed scaffolds require residual monomer testing and ISO 10993-1:2018 biocompatibility evaluation for patient-specific implants; ASTM F2150-19 gives structural characterization methods for tissue-engineered scaffolds, ISO/ASTM 52900:2021 covers additive-manufacturing process terminology and documentation, and ISO 13781:2017 governs in vitro degradation. Published data for PLD 9655 specifically in fused filament fabrication remains limited; the above processing envelope is derived from documented 96:4 lactide-copolymer extrusion and clinical additive-manufacturing validation reports. Terminal product types include patient-specific cranial defect scaffolds, maxillary sinus floor grafts, and load-sharing osteochondral plugs.